|
gptkbp:instanceOf
|
gptkb:drug
anticonvulsant
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2016
|
|
gptkbp:ATCCode
|
N03AX23
|
|
gptkbp:brand
|
gptkb:Briviact
|
|
gptkbp:CASNumber
|
357336-20-0
|
|
gptkbp:developedBy
|
gptkb:UCB_Pharma
|
|
gptkbp:eliminationHalfLife
|
7-8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C11H20N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
brivaracetam
|
|
gptkbp:IUPACName
|
(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide
|
|
gptkbp:KEGGID
|
D10560
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to synaptic vesicle protein 2A (SV2A)
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
~17.5%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105757
9837247
DB06220
8013128
|
|
gptkbp:relatedTo
|
gptkb:levetiracetam
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
irritability
somnolence
|
|
gptkbp:synonym
|
gptkb:UCB-34714
|
|
gptkbp:UNII
|
6H8N5N7E5B
|
|
gptkbp:usedFor
|
epilepsy
partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:Briviact
|
|
gptkbp:bfsLayer
|
8
|